Respiratory Research

Table 3 Results of base case NMA: Difference in intervention versus the comparator for CFB in SGRQ total score at 6 months, 95% credible intervals, and probability that the intervention is better than the comparator

From: Comparative efficacy of long-acting bronchodilators for COPD - a network meta-analysis

Intervention		Comparator
Intervention		PLACEBO		TIO 18		SAL 50		FOR 12		TIO 5		IND 150		IND 300		GPM 50
PLACEBO	estimate	0.00		2.63		1.31		2.58		2.21		3.87		3.57		3.18
	95% CrI			1.91	3.31	0.48	2.21	0.60	4.53	0.78	3.61	2.56	5.17	2.30	4.84	1.78	4.56
	P(better)			<1%		<1%		1%		<1%		<1%		<1%		<1%
TIO 18	estimate	−2.63		0.00		−1.32		−0.05		−0.42		1.24		0.94		0.55
	95% CrI	−3.31	−1.91			−2.32	−0.21	−2.09	2.01	−1.98	1.17	−0.15	2.63	−0.41	2.31	−0.92	2.04
	P(better)	>99%				99%		52%		72%		4%		8%		22%
SAL 50	estimate	−1.31		1.32		0.00		1.27		0.91		2.56		2.26		1.87
	95% CrI	−2.21	−0.48	0.21	2.32			−0.92	3.36	−0.82	2.50	1.03	4.00	0.74	3.75	0.21	3.44
	P(better)	>99%		1%				12%		13%		<1%		<1%		1%
FOR 12	estimate	−2.58		0.05		−1.27		0.00		−0.37		1.30		1.00		0.61
	95% CrI	−4.53	−0.60	−2.01	2.09	−3.36	0.92			−2.78	2.05	−0.97	3.56	−0.96	2.98	−1.81	3.02
	P(better)	99%		48%		88%				62%		13%		16%		31%
TIO 5	estimate	−2.21		0.42		−0.91		0.37		0.00		1.67		1.36		0.97
	95% CrI	−3.61	−0.78	−1.17	1.98	−2.50	0.82	−2.05	2.78			−0.29	3.58	−0.53	3.26	−1.01	2.94
	P(better)	>99%		28%		87%		38%				4%		7%		15%
IND 150	estimate	−3.87		−1.24		−2.56		−1.30		−1.67		0.00		−0.30		−0.70
	95% CrI	−5.17	−2.56	−2.63	0.15	−4.00	−1.03	−3.56	0.97	−3.58	0.29			−1.82	1.24	−2.59	1.28
	P(better)	>99%		96%		>99%		87%		96%				65%		77%
IND 300	estimate	−3.57		−0.94		−2.26		−1.00		−1.36		0.30		0.00		−0.39
	95% CrI	−4.84	−2.30	−2.31	0.41	−3.75	−0.74	−2.98	0.96	−3.26	0.53	−1.24	1.82			−2.28	1.47
	P(better)	>99%		92%		>99%		84%		93%		35%				66%
GPM 50	estimate	−3.18		−0.55		−1.87		−0.61		−0.97		0.70		0.39		0.00
	95% CrI	−4.56	−1.78	−2.04	0.92	−3.44	−0.21	−3.02	1.81	−2.94	1.01	−1.28	2.59	−1.47	2.28
	P(better)	>99%		78%		99%		69%		85%		23%		34%

95% CrI = 95% Credible Interval; P(better) = Probability of being the treatment being better than the comparator in terms of the outcome assessed; CFB = Change from baseline; FOR 12 = Formoterol 12 μg twice daily (BID); GPM 50 = Glycopyrronium 50 μg once daily (OD); IND 150 = Indacaterol 150 μg OD; IND 300 = Indacaterol 300 μg OD; SAL 50 = Salmeterol 50 μg BID; SGRQ = St. George’s Respiratory Questionnaire; TIO 5 = Tiotropium 5 μg OD; TIO 18 = Tiotropium 18 μg OD.

Back to article page

ISSN: 1465-993X

Contact us

General enquiries: journalsubmissions@springernature.com